Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BVC4
UPID:
LST8_HUMAN
Alternative names:
G protein beta subunit-like; Mammalian lethal with SEC13 protein 8
Alternative UPACC:
Q9BVC4; B3KMM4; B4DY00; D3DU88; Q5M800; Q86Y18; Q8WUI5; Q9HA66; Q9UJV6
Background:
The Target of rapamycin complex subunit LST8, also known as G protein beta subunit-like and Mammalian lethal with SEC13 protein 8, plays a pivotal role in cell growth and survival. It is a crucial component of both mTORC1 and mTORC2 complexes, influencing protein synthesis, ribosome synthesis, and actin cytoskeleton regulation through various signaling pathways, including AKT1-mediated phosphorylation and amino acid signaling.
Therapeutic significance:
Understanding the role of Target of rapamycin complex subunit LST8 could open doors to potential therapeutic strategies.